BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 01, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Humira adalimumab regulatory update

Abbott said its Humira adalimumab was approved in Japan to treat psoriasis and psoriatic arthritis. The human mAb...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >